1.99 0.00 (0.00%)
After hours: 4:52PM EDT
|Bid||1.90 x 1800|
|Ask||2.05 x 3000|
|Day's Range||1.90 - 2.01|
|52 Week Range||1.70 - 5.36|
|Beta (3Y Monthly)||-1.33|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2018 - Mar 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.75|
Investors need to pay close attention to CTI BioPharma (CTIC) stock based on the movements in the options market lately.
SEATTLE, Oct. 1, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) today announced that following a planned second interim data review of the PAC203 study by the Independent Data Monitoring Committee (IDMC), the study will continue to the full enrollment of 150 patients. The IDMC did not identify significant drug- or dose-related safety concerns and specifically did not identify any concerns around hemorrhagic or cardiac toxicity.
SEATTLE , Sept. 26, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cantor Fitzgerald Global Healthcare ...
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / CTI BioPharma Corp. (NASDAQ: CTIC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern Time. ...
CTI BioPharma (CTIC) delivered earnings and revenue surprises of 13.04% and 104.33%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Seattle-based company said it had a loss of 20 cents per share. The biotechnology company posted revenue of $613,000 in the period. The company's shares closed at $2.25. A year ago, they were trading ...
-Management to Host Conference Call/Webcast Today at 4:30 p.m. Eastern Time- SEATTLE , Aug. 2, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported financial results for the second quarter ...
SEATTLE , July 26, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its second quarter 2018 financial results on Thursday, August ...
CTI BioPharma (CTIC) conducts Type B meeting with the FDA to discuss a regulatory pathway for its lead pipeline candidate Pacritinib, currently under study for the treatment of myelofibrosis.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 18) Abbott Laboratories (NYSE: ABT )(reported better-than-expected ...
NEW YORK, NY / ACCESSWIRE / July 19, 2018 / Shares of CTI Biopharma tanked nearly 44% yesterday while shares of Crinetics Pharmaceuticals exploded 44%. The former announced an update from an FDA meeting regarding the company's investigational drug pacritinib. Per FDA feedback, the company will now have to conduct a Phase 3 trial.
Why Is CTI BioPharma Stock Down Today? On July 18, CTI BioPharma (CTIC) announced the outcome of its type B meeting with the FDA related to its investigational drug pacritinib. As per the FDA’s feedback, the company now needs to conduct a Phase 3 trial to evaluate this second-generation JAK2 inhibitor for the treatment of myelofibrosis patients suffering from thrombocytopenia or who have already been treated with ruxolitinib.
SEATTLE, July 18, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) today announced that it recently conducted a Type B meeting with the U.S. Food and Drug Administration (FDA) for its lead product candidate pacritinib. The purpose of the meeting was to discuss the regulatory pathway for pacritinib. Based on FDA feedback, the Company plans to conduct a randomized Phase 3 study in patients with myelofibrosis.
Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.
CTI BioPharma (CTIC) and partner Servier announce that a pivotal study evaluating a Pixuvri combination regimen in non-Hodgkin lymphoma fails to improve progression free survival.
Stocks that moved substantially or traded heavily Monday: Groupon Inc., up 47 cents to $4.83 Recode reported that the online coupon company is looking for a buyer. Twitter Inc., down $2.51 to $44.14 The ...
CTI Biopharma Corp said on Monday its treatment for a type of blood cancer did not meet the main goal of a late-stage trial. The drug, Pixuvri, did not show a statistically significant improvement in the length of time patients survived without any progression in the disease. CTI's treatment was being tested in combination with Roche Holding's Rituxan in patients with aggressive B-cell Non-Hodgkin lymphoma.
CTI Biopharma Corp said on Monday its treatment for a type of blood cancer did not meet the main goal of a late-stage trial. The drug, Pixuvri, was being tested in patients with aggressive B-cell Non-Hodgkin ...